HOME >> BIOLOGY >> NEWS
JCI table of contents: June 14, 2007

EDITOR'S PICK

Hot on the TRAIL of controlling inflammation in bacterial meningitis

In a study appearing online on June 14 in advance of publication in the July print issue of the Journal of Clinical Investigation, researchers at Charite Universitatsmedizin Berlin report that the molecule known as TRAIL can limit excessive immune responses in bacterial meningitis and as such may be of use to control inflammation of the spinal cord and brain, which causes brain cell death in this life-threatening disease.

Pneumococcal meningitis involves inflammation of the protective membranes covering the brain and spinal cord and is caused by infection with the bacterium Streptococcus pneumoniae. The observed swelling of the brain is largely the result of the excessive immune response to infection. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been previously reported to play a role in the regulation of the host immune response. In the current study, Joerg Weber and colleagues administered components of Streptococcus pneumoniae bacteria to the cerebrospinal fluid bathing the brain and spinal cord of mice lacking TRAIL. They found that these animals suffered from increased inflammation and brain cell death, however these effects were reversed by the administration of recombinant TRAIL (rTRAIL). Importantly, the application of rTRAIL to mice with intact TRAIL and meningitis also decreased inflammation and neuronal cell death. Finally, the authors observed that human patients with bacterial meningitis showed increased synthesis in the cerebrospinal fluid of TRAIL. The results of the study provide evidence that TRAIL acts to limit inflammation of the brain and spinal cord during bacterial meningitis, suggesting that it may be of use as an anti-inflammatory agent in invasive bacterial infections.

TITLE: TRAIL limits excessive host immune responses in bacterial meningitis

AUTHOR CONTACT:
Joerg W
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
14-Jun-2007


Page: 1 2 3 4 5 6 7

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. Food safety begins as vegetables grow
11. Turning the tables in chemistry

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2020)... ... , ... Shoreline Biome , a microbiome research company that develops tools ... will debut a novel new DNA isolation kit at the Miami Winter Symposium ... Prep kit, is a fast and easy-to-use kit designed for the efficient and unbiased ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN has developed ... cells. The red blood cells are made utilizing a bioreactor that permits ... therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN ...
(Date:1/22/2020)... , ... January 21, 2020 , ... ... to lead the company’s new Business Development Department. The move, which is part ... had been previously serving as the company’s Senior Vice President where he oversaw ...
Breaking Biology News(10 mins):
(Date:1/28/2020)... ... January 28, 2020 , ... ... the exclusive distributor to food and beverage manufactures within North America. Both Lifecycle ... suppliers. This agreement will allow each company to pool their collective resources and ...
(Date:1/28/2020)... STATE COLLEGE, Pa. (PRWEB) , ... January 28, ... ... trusted line of Better Salivary Assay Kits . The new Salivary ... salivary bioscience research. “By measuring total immunoglobulin G in saliva, researchers can extend ...
(Date:1/27/2020)... ... January 27, 2020 , ... Valencell, ... financing from strategic investors led by Halma plc , a FTSE 100 ... TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma will ...
(Date:1/24/2020)... ... January 24, 2020 , ... The impact ... biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two decades of ... world. And as Slone Partners celebrates its 20th anniversary this year, ...
Breaking Biology Technology:
Cached News: